+

WO1996003154A1 - Utilisation de chelates en tant qu'agents de contraste pour rayons x - Google Patents

Utilisation de chelates en tant qu'agents de contraste pour rayons x Download PDF

Info

Publication number
WO1996003154A1
WO1996003154A1 PCT/EP1995/002901 EP9502901W WO9603154A1 WO 1996003154 A1 WO1996003154 A1 WO 1996003154A1 EP 9502901 W EP9502901 W EP 9502901W WO 9603154 A1 WO9603154 A1 WO 9603154A1
Authority
WO
WIPO (PCT)
Prior art keywords
dtpa
use according
chelates
rays
diagnostics
Prior art date
Application number
PCT/EP1995/002901
Other languages
German (de)
English (en)
Inventor
Werner Krause
Ulrich Speck
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Priority to AU31643/95A priority Critical patent/AU3164395A/en
Priority to EP95927704A priority patent/EP0772458A1/fr
Priority to JP8505459A priority patent/JPH10502935A/ja
Publication of WO1996003154A1 publication Critical patent/WO1996003154A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations

Definitions

  • the invention relates to the use of water-soluble, metal-containing chelates.
  • the X-ray contrast media currently available for uro / angiography and computer tomography are compounds that are based exclusively on triiodoaromatics. Examples include amidotrizoate (ionic monomer), iohexol, iopamidol, iopromide, iopentol, ioversol (nonionic monomers), ioxaglate (ionic dimer), iotrolan and iodixanol (nonionic dimers).
  • iodine-containing contrast agents are known, but have not yet gained any practical importance, although the need for these compounds is very high.
  • a disadvantage of the iodine-containing contrast agents is that there are always free iodine ions in the formulation, which can lead to complications in the thyroid gland.
  • An overactive thyroid can lead to a hyperthyroid metabolic state if the iodide supply is greatly increased by the injection of a contrast medium containing iodine (iodide).
  • iodide contrast medium containing iodine
  • the dose In order to be able to use lanthanide-containing contrast media in X-ray diagnostics, the dose must be increased by a factor of 10 compared to the dose customary in MR diagnostics, which, however, has the disadvantageous consequence that such contrast media are no longer compatible with the patient.
  • gadolinium- or ytterbium-containing contrast agents can be used using synchrotron radiation, although no information is given about the chosen concentration.
  • the object of the invention is to find a replacement for iodine-containing contrast agents in X-ray diagnostics, these contrast agents also being said to be suitable for humans.
  • water-soluble, metal-containing chelates with the elements of atomic numbers 40-42, 50, 51, 56-78, 80, 82 and 83 which do not contain iodine can then be used as X-ray contrast agents if instead of those in the usual way X-ray equipment or CT equipment used x-ray radiation synchrotron radiation is used.
  • the contrast media are preferably used in the formulation and dosage customary for MR diagnostics.
  • monochromatic X-rays can also be used, almost monochromatic X-rays or X-rays above a defined energy range, ie above the K edge of the metal atom contained in the chelates, are used.
  • the advantages of the new method for synchrotron CT are that, firstly, lower-dose and better-tolerated MR contrast agents can be used instead of iodine-containing contrast agents, and secondly that there are no free iodine ions that can lead to thyroid complications.
  • Another advantage is that with higher-energy radiation, the OK edge of gadolinium (51 keV instead of 33 keV for iodine) can be used. Higher radiation energy means that the ionizing effect is significantly reduced, so that the patient's radiation exposure is less important.
  • the energy of the radiation can be adjusted so that it is closer to the K edge than when using the subtraction method in which recordings are made below and above the K edge of the respective contrast medium conventional X-rays is possible due to the wavelength distribution.
  • This allows a significant increase in contrast to be achieved.
  • This increase in contrast is surprisingly so great that even contrast media with a very high osmolality, relatively low solubility in water, or substances which develop such high viscosities in solution that they are only sufficiently thin in a highly diluted form, can be used.
  • novel contrast effects that were previously inaccessible in x-rays or at least not achievable with compatible doses are achieved.
  • the following substances are particularly suitable as metal-containing contrast agents:
  • Lanthanide complexes of the following chelating agents DTPA, DOTA, HP-D03A, EOB-DTPA, BOPTA and DTPA-polylysine and other high molecular complexing agents or macromolecules containing complexing agents see e.g. EP 0430863.
  • the molecular weight of the high molecular weight compounds is preferably> 10000 D.
  • modified complexes such as that Gd-EOB-DTPA are particularly well suited for liver imaging.
  • contrast media which have heavier elements, such as bismuth, lead or tantalum, also have advantages as X-ray contrast media.
  • contrast agents containing tantalum were discussed in DE-OS 28 31 524, but only for conventional polychromatic X-rays and mostly as water-insoluble tantalum powder. With such contrast media, too, it has been found that using synchrotron radiation offers great advantages with regard to the detection of special structures in the body and their diseases.
  • GD-DTPA is administered intravenously in the formulation of 0.5 mol / l, which is customary for MR diagnostics, and in the dosage of 0.1-0.3 mmol / kg of body weight, which is customary for MR diagnostics.
  • an electron storage ring e.g. DESY in Hamburg, 5.8 GeV storage ring at the University of Tskukuba in Ibaraki, Japan or other institutes
  • blood vessels, organs and tissues could be displayed in a much higher contrast according to their blood content, perfusion and the proportion of extracellular space than was previously possible.
  • the recording device consists of a 2.5 GeV storage ring (260 mA, 5T Wiggler) as a light source, a movable silicone plate as a monochromator, a Gd filter for the 2-energy display and an amplifier as a detector.
  • the images are recorded at intervals of 32 msec, once above the K edge of Gd (51 keV) and once below the K edge. After subtracting the two images, blood vessels are displayed.
  • Gd-DOTA is administered intravenously in the formulation of 0.5 mol / l, which is customary for MR diagnostics, and in the dosage of 0.1, 0.3 mmol / kg, which is customary for MR diagnostics.
  • the admission takes place according to the procedure described for Gd-DTPA.
  • Gd-HP-DO3A is administered intravenously in the formulation of 0.5 mol / l customary for MR diagnostics and in the dosage of 0.1 - 0.3 mmol / kg body weight customary for MR diagnostics.
  • the admission takes place according to the procedure described for Gd-DTPA.
  • up to 1 mmol / kg can also be administered. In this case, a particularly high detection sensitivity for tumors and infarcts is achieved.
  • Gd-EOB-DTPA is administered intravenously in the formulation of 1 mol / l customary for MR diagnostics and in the dosage customary for MR diagnostics of 0.01 to 0.3 mmol / kg body weight.
  • the liver can be visualized using synchrotron radiation, since Gd-EOB-DTPA is absorbed by the hepatocytes.
  • Gd-EOB-DTPA is absorbed by the hepatocytes.
  • the uptake takes place 10 minutes to 1 hour after administration in the procedure described for Gd-DTPA.
  • Er-EOB-DTPA is administered intravenously in the formulation customary for MR diagnostics and in the dosage customary for MR diagnostics of 0.01 to 0.3 mmol / kg body weight.
  • Dy-DTPA-polylysine is administered intravenously in the formulation and dose customary for Gd-DTPA in MR diagnostics (G. Schuhmann-Giampieri, H. Schmitt-Willich, T. Frenzel, WR Press, HJ Weinmann, Invest. Radiol. 26: 969-74, (1991)).
  • This substance can be used to display the intravascular space using synchrotron radiation, since the contrast medium is able to remain within the vascular system over a longer period of time. With rapid admission sequences, the tissue perfusion can also be recorded exactly. There is no example of this in the field of classic X-ray contrast media and using conventional X-rays.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne l'utilisation de chélates métalliques hydrosolubles, en tant qu'agents de contraste pour rayons X, avec un rayonnement synchrotron.
PCT/EP1995/002901 1994-07-26 1995-07-21 Utilisation de chelates en tant qu'agents de contraste pour rayons x WO1996003154A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU31643/95A AU3164395A (en) 1994-07-26 1995-07-21 Use of chelates as x-ray contrast mediums
EP95927704A EP0772458A1 (fr) 1994-07-26 1995-07-21 Utilisation de chelates en tant qu'agents de contraste pour rayons x
JP8505459A JPH10502935A (ja) 1994-07-26 1995-07-21 Ｘ線造影剤としてのキレートの使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4426438.0 1994-07-26
DE4426438A DE4426438A1 (de) 1994-07-26 1994-07-26 Verwendung von Chelaten als Röntgenkontrastmittel

Publications (1)

Publication Number Publication Date
WO1996003154A1 true WO1996003154A1 (fr) 1996-02-08

Family

ID=6524171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002901 WO1996003154A1 (fr) 1994-07-26 1995-07-21 Utilisation de chelates en tant qu'agents de contraste pour rayons x

Country Status (7)

Country Link
EP (1) EP0772458A1 (fr)
JP (1) JPH10502935A (fr)
AU (1) AU3164395A (fr)
DE (1) DE4426438A1 (fr)
IL (1) IL114710A0 (fr)
WO (1) WO1996003154A1 (fr)
ZA (1) ZA956227B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501223B2 (en) 2003-06-20 2013-08-06 Hill's Pet Nutrition, Inc. Methods for dietary management of cats to avoid hyperthyroidism

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4789096A (en) * 1995-02-09 1996-08-27 Schering Aktiengesellschaft Liposomes containing contrast media for blood pool imaging
EP1136082A1 (fr) * 2000-03-24 2001-09-26 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Administration locale de médicaments
DE10118792B4 (de) * 2001-04-05 2005-12-22 Schering Ag Anordnung zur Aufnahme von Projektionsmammogrammen und Verwendung der Anordnung für die Projektionsmammographie
JP4586018B2 (ja) * 2003-06-20 2010-11-24 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 猫における甲状腺機能亢進症を予防する方法及び限定されたヨウ素を含む組成物
US9132207B2 (en) 2009-10-27 2015-09-15 Spine Wave, Inc. Radiopaque injectable nucleus hydrogel compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432370A (en) * 1981-10-14 1984-02-21 The Board Of Trustees Of The Leland Stanford Junior University Method and means for minimally invasive angiography using mono-chromatized synchrotron radiation
US4478816A (en) * 1982-06-07 1984-10-23 Georgetown University Rare earth/chelating agent complex for digital fluoroscopy
EP0430863A2 (fr) * 1989-11-21 1991-06-05 Schering Aktiengesellschaft Formateur de complexe lié à un polymère préparé par étapes, ses complexes et conjugats, procédé de préparation et substances pharmaceutiques les contenant
WO1993016375A1 (fr) * 1992-02-06 1993-08-19 Mallinckrodt Medical, Inc. Agents de contraste utilises pour les radiographies et l'irm

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432370A (en) * 1981-10-14 1984-02-21 The Board Of Trustees Of The Leland Stanford Junior University Method and means for minimally invasive angiography using mono-chromatized synchrotron radiation
US4478816A (en) * 1982-06-07 1984-10-23 Georgetown University Rare earth/chelating agent complex for digital fluoroscopy
EP0430863A2 (fr) * 1989-11-21 1991-06-05 Schering Aktiengesellschaft Formateur de complexe lié à un polymère préparé par étapes, ses complexes et conjugats, procédé de préparation et substances pharmaceutiques les contenant
WO1993016375A1 (fr) * 1992-02-06 1993-08-19 Mallinckrodt Medical, Inc. Agents de contraste utilises pour les radiographies et l'irm

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 113, no. 9, 27 August 1990, Columbus, Ohio, US; abstract no. 73900, ZEMAN, H. D. ET AL: "Contrast agent choice for intravenous coronary angiography" *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; *
DIX W.R.: "INTRAVENOUS CORONARY ANGIOGRAPHY WITH SYNCHRTRON RADIATION.", PROGRESS IN BIOPHYSICS AND MOLECULAR BIOLOGY, vol. 63, no. 2, pages 159 - 191 *
NUCL. INSTRUM. METHODS PHYS. RES., SECT. A (1990), A291(1-2), 67-73 CODEN: NIMAER;ISSN: 0168-9002 *
O' HARE N.J.: "CONTRAST AGENT CT IMAGING IN VARIABLE SIZED ORGANS USING SINGLE ENERGY SYNCHROTRON RADIATION.", PHYS. MED. BIOL., vol. 37, no. 7, pages 1519 - 1530, XP000280557, DOI: doi:10.1088/0031-9155/37/7/004 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501223B2 (en) 2003-06-20 2013-08-06 Hill's Pet Nutrition, Inc. Methods for dietary management of cats to avoid hyperthyroidism

Also Published As

Publication number Publication date
IL114710A0 (en) 1995-11-27
ZA956227B (en) 1996-03-14
JPH10502935A (ja) 1998-03-17
AU3164395A (en) 1996-02-22
DE4426438A1 (de) 1996-02-01
EP0772458A1 (fr) 1997-05-14

Similar Documents

Publication Publication Date Title
DE69121562T3 (de) Kontrastmittel enthaltend einen nicht-ionischen kontrast Wirkstoff und Sodium und Kalzium Sälze
DE2717819A1 (de) Kontrastmedium fuer roentgenlicht
DE2547376C2 (de) Zubereitung für die Knochenuntersuchung, Verfahren zu ihrer Herstellung und ihre Verwendung
DE102005052368B4 (de) Röntgensystem zur Erstellung diagnostischer Röntgendarstellungen unter Applikation von Kontrastmitteln
DE102005026940A1 (de) Röntgenanordnung zur Bilddarstellung eines Untersuchungsobjektes und Verwendung der Röntgenanordnung
DE69020208T2 (de) Kontrastmittel.
DE69033953T2 (de) Kolloidale radiomarkierte zusammensetzungen, deren anwendung und verfahren zu deren herstellung
EP0772458A1 (fr) Utilisation de chelates en tant qu'agents de contraste pour rayons x
EP0994729B1 (fr) Utilisation d'agents de contraste intraveineux pour mammographie avec projection
DE2708324A1 (de) Radioaktiv markiertes scanningmittel
DE60216770T2 (de) Ionisches und nicht-ionisches radiographisches kontrastmittel zur verwendung in der kombinierten roentgen- und kernspintomographiediagnostik
WO1999042139A2 (fr) Conjugues d'amidon hydroxyethyle, leur procede de production et produits pharmaceutiques les contenant
Schmitz et al. Evaluation of gadobutrol in a rabbit model as a new lanthanide contrast agent for computed tomography
DE68924837T2 (de) Kernspinsresonanzabbildungsverfahren.
DE4426439C1 (de) Kontrastmittel zur Darstellung der Leber
WO2005034755A1 (fr) Systeme radiographique et procede de contraste radiographique pour formation d'image sur un objet d'examen contenant au moins un element engendrant un contraste radiographique et utilisation dudit systeme radiographique
DE1932231A1 (de) Diagnostisches und therapeutisches Praeparat auf der Basis eines chelatgebundenen Radio-Nuclids
DE69428554T2 (de) Mittel zum Vermeiden des Verklebens von Thallium 201 zu einer Container
DE19606326A1 (de) Kontrastmittelhaltige Liposomenformulierung sowie deren Verwendung für die In-vivo-Diagnostik, insbesondere für die Darstellung des Intravasalraumes
DE102022205295B4 (de) Verfahren zur Mehrenergie-Röntgenbildgebung, Röntgeneinrichtung, Behandlungssystem, Computerprogramm und elektronisch lesbarer Datenträger
DE19627309C2 (de) Wäßrige injizierbare Formulierungen verwendbar als Kontrastmittel
DE2124751A1 (de) Verfahren zur Herstellung eines diagnostischen Präparats auf Basis eines mit 99mTc markierten Eisenkomplexes
Wilcox et al. Effect of intravenous contrast material on the integrity of the blood-brain barrier: experimental study.
DE3524004A1 (de) Generator fuer kurzlebige radionuclide
DE740543C (de) Roentgenkontrastmittel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BY CA CN CZ FI HU JP KR MX NO NZ PL RU SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995927704

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 776153

Date of ref document: 19970402

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995927704

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995927704

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载